DMDomenico Martire

Domenico Martire

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Domenico Martire has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reply to Yavuz, S. Comment on “Martire et al. Prognostic Role of High-Sensitivity C-Reactive Protein/Albumin Ratio in Heart Failure Patients. Biomedicines 2026, 14, 748”

    by Domenico Martire, Giuseppe Armentaro, Giandomenico Severini, Carlo Alberto Pastura, Maria Rosangela Scarcelli, Velia Cassano, Martina Crasà, Ilaria Gareri, Gianluca Cortese, Valentino Condoleo, et al.

    We would like to thank the author for the careful evaluation of our manuscript and for the thoughtful comments

  • Open Access

    Prognostic Role of High-Sensitivity C-Reactive Protein/Albumin Ratio in Heart Failure Patients

    by Domenico Martire, Giuseppe Armentaro, Giandomenico Severini, Carlo Alberto Pastura, Maria Rosangela Scarcelli, Velia Cassano, Martina Crasà, Ilaria Gareri, Gianluca Cortese, Valentino Condoleo, et al.

    The ratio of high-sensitivity C-reactive protein (hs-CRP) to Serum albumin (SA) (hs-CRP/SA) is emerging as a new potential biomarker capable of stratifying cardiovascular risk in patients with chronic HF (CHF), particularly the risk of major adverse cardiovascular events (MACEs). Objectives: The aim of this study was to evaluate the long-term prognostic value of the hs-CRP/SA ratio on the risk of MACEs in a population of outpatients with CHF. Methods: In this retrospective observational study, 500 patients were enrolled and were stratified into two groups based on the median value of the hs-CRP/SA ratio: 249 patients with hs-CRP/SA < 1.19 and 251 patients with hs-CRP/SA ≥ 1.19. Results: During median follow-up of 5.2 years, 3.6 MACEs/100 patients/year were detected; patients with hs-CRP/SA ≥ 1.19 had a MACE incidence of 5.9 events per 100 patient-years, compared with 1.2 events per 100 patient-years in those with hs-CRP/AS < 1.19 (p < 0.001). Multivariate analysis confirmed that hs-CRP/SA ≥ 1.19 was associated with an approximately 6.5-fold increased risk of new MACEs (HR 6.513, 95% CI 3.928–10.797; p < 0.001). Conclusions: The hs-CRP/SA ratio is confirmed as a powerful prognostic marker in patients with CHF, associated with a significantly increased risk of MACEs.


  • Open Access

    Circulating Biomarkers in Elderly Patients with Heart Failure: A Real-Life Study

    by Velia Cassano, Caterina Gabriele, Maria Rosangela Scarcelli, Giuseppe Armentaro, Giandomenico Severini, Domenico Martire, Carlo Alberto Pastura, Sofia Miceli, Marta Letizia Hribal, Giuseppe Massimo Claudio Rosano, et al.

    Background: Heart failure (HF) is a clinical syndrome that involves multiple interconnected pathways. Circulating biomarkers in HF emerged as powerful tools for risk stratification, diagnostic confirmation, prognostic assessment, and monitoring of treatment efficacy. The aim of the present study was to evaluate circulating levels of biomarkers in elderly patients with improved HF ejection fraction, previously with left ventricular ejection fraction (LVEF) p < 0.001). Proteomic analysis revealed selective changes in key cardiovascular (CV)-related proteins, such as insulin-like growth factor-binding protein 4 (IBP4), thrombospondin-4 (TSP4), intercellular adhesion molecule 1 (ICAM1), and syndecan-4 (SDC4). Conclusions: This study demonstrates significant improvements across multiple CV biomarkers after six months of therapy optimisation in HFimpEF patients, providing evidence for comprehensive therapeutic effects targeting inflammation, oxidative stress, neurohormonal activation, and thrombotic risk.


  • Open Access

    Circulating Biomarkers in Elderly Patients with Heart Failure: A Real-Life Study

    by Velia Cassano, Caterina Gabriele, Maria Rosangela Scarcelli, Giuseppe Armentaro, Giandomenico Severini, Domenico Martire, Carlo Alberto Pastura, Sofia Miceli, Marta L. Hribal, Giuseppe M.C. Rosano, et al.

    BACKGROUND: Heart failure (HF) is a clinical syndrome that involves multiple interconnected pathways. Circulating biomarkers in HF emerged as powerful tools for risk stratification, diagnostic confirmation, prognostic assessment, and monitoring of treatment efficacy. The aim of the present study was to evaluate circulating levels of biomarkers in elderly patients with HF improved ejection fraction, previously with left ventricular ejection fraction (LVEF) METHODS: We enrolled 100 HFimpEF outpatients. All patients underwent medical history and physical examination, at the baseline and after 6 months of follow-up. The serum values of circulating biomarkers were assessed with ELISA test. Proteomic analysis was performed on serum samples collected from a subset of 13 patients at baseline and after 6 months of follow-up. RESULTS: At follow-up, we observed significant improvements in glycometabolic, renal and inflammatory profile (pCONCLUSIONS: This study demonstrates significant improvements across multiple CV biomarkers, after 6 months of therapy optimization, in HFimpEF patients, providing evidence for comprehensive therapeutic effects targeting inflammation, oxidative stress, neurohormonal activation, and thrombotic risk.